TXG earnings

PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026. Recent Updates Revenue was $150.8 million for the first quarter of 2026, representing a 3% decrease over the corresponding period of 2025. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.Launched Atera, a new platform to redefine how biology is measured and understood.

PLEASANTON, Calif., April 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2026 after market close on Thursday, May 7, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's

PLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026. Recent Updates Revenue was $166.0 million for the fourth quarter of 2025, representing a 1% increase over the corresponding period of 2024. Revenue was $642.8 million for the full year of 2025. Excluding $44.1 million of non-recurring revenue related to patent litigation settlements, full-year revenue was $598.7 million, rep

PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Thursday, February 12, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

PLEASANTON, Calif., Nov. 6, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2025. Recent Updates Revenue was $149.0 million for the third quarter, compared to $172.9 million in the second quarter, which included $27.3 million related to one-time license and royalty revenue. Third quarter revenue represents a 2% increase sequentially, excluding the second quarter one-time license and royalty revenue.Started shipping the next-generation of Chromium Flex,

PLEASANTON, Calif., Oct. 9, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 6, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025. Recent Updates Revenue was $172.9 million for the second quarter. Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million.Ended the second quarter with cash and cash equivalents and marketable securities of $447.3 million, representing a $20 million increase over the prior quarter.Entered into a definitive agreement to acquire Scale Biosc

PLEASANTON, Calif., July 10, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the second quarter ended June 30, 2025 after market close on Thursday, August 7, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

PLEASANTON, Calif., Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025. Recent Updates Revenue was $165.0 million for the fourth quarter and $610.8 million for the full year of 2024, representing 10% and 1% decreases over the corresponding periods of 2023.In collaboration with the Chan Zuckerberg Initiative (CZI) and Ultima Genomics, launched the Billion Cells Project, an effort to generate an unpre

PLEASANTON, Calif., Jan. 28, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Wednesday, February 12, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

PLEASANTON, Calif., Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue was $151.7 million for the third quarter, in line with the company's preliminary announcement, a 1% decrease over the corresponding period of 2023, primarily driven by lower instrument revenue, offset by stronger contributions from consumables.Began shipping GEM-X Flex, setting a new standard for the cost per cell for researchers and enabling the

PLEASANTON, Calif., Oct. 9, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024. Preliminary Select Third Quarter 2024 Results Revenue of approximately $151.7 million for the third quarter ended September 30, 2024, representing an approximate 1% decrease from the corresponding prior year period.Preliminary revenue by source for the third quarter is expected to be as follows:Instruments revenue of approximately $19.1 million, representing a 46

PLEASANTON, Calif. , Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by stronger contributions from consumables.Began shipping Xenium Prime 5K, which measures 5,000 genes and features an enhanced chemistry to deliver excellent per-gene sensitivity, improved specificity and spatial fidelity, and integrated m

PLEASANTON, Calif., July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thursday, August 8, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

PLEASANTON, Calif., April 30, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Revenue was $141.0 million for the first quarter, a 5% increase over the corresponding period of 2023, driven by Spatial revenue.Shipped Visium HD Spatial Gene Expression, enabling whole transcriptome spatial discovery at single cell-scale resolution.Shipped two major new Chromium products powered by GEM-X, the next generation of the company's leading singl

PLEASANTON, Calif., April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022 PLEASANTON, Calif., Feb. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided outlook for 2024. Recent Highlights Revenue was $184.0 million for the fourth quarter and $618.7 million for the full year of 2023, representing 18% and 20% increases over the corresponding periods of 2022.Increased cumulative instruments sold t

PLEASANTON, Calif., Jan. 24, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after market close on Thursday, February 15, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

PLEASANTON, Calif., Oct. 11, 2023 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today it will report financial results for the third quarter 2023 after market close on Thursday, November 2, 2023. The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call. Live

PLEASANTON, Calif., Aug. 3, 2023 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Revenue was $146.8 million for the second quarter, representing a 28% increase over the corresponding period of 2022.Accelerated Xenium's momentum with strong shipments, multiple new curated and customizable gene panels and a major update of its onboard software to deliver even higher levels of performance.Launched the Visium CytAssist Gene and Protein Expres

PLEASANTON, Calif., July 13, 2023 /PRNewswire/ -- 10x Genomics (NASDAQ:TXG), a leader in single cell and spatial biology, announced today it will report financial results for the second quarter 2023 after market close on Thursday, August 3, 2023. The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call. Live audio o

PLEASANTON, Calif., May 3, 2023 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG) today reported financial results for the first quarter ended March 31, 2023. Recent Highlights Revenue was $134.3 million for the first quarter, representing a 17% increase over the corresponding period of 2022.Surpassed 5,000 customer publications using 10x Genomics products, demonstrating the impact of single cell and spatial technologies to fuel new biological discoveries.Accelerated Spatial revenue growth driven by robust demand for Xenium in its first full quarter of commercial launch and cont

PLEASANTON, Calif., April 12, 2023 /PRNewswire/ -- 10x Genomics (NASDAQ:TXG), a life sciences leader focused on mastering biology to advance human health, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023. The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.  The news release with the financial results will be accessible from the company's website prior to the conference call.

Q4 2022 revenue growth of 9% and FY 2022 revenue growth of 5% over the corresponding periods of 2021 PLEASANTON, Calif., Feb. 15, 2023 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided outlook for 2023. Recent Highlights Revenue was $156.2 million for the fourth quarter and $516.4 million for the full year of 2022, representing 9% and 5% increases over the corresponding periods of 2021.Increased cumulative instruments sold to more than 4,600 as of the end of 2022, driven by

PLEASANTON, Calif., Jan. 19, 2023 /PRNewswire/ -- 10x Genomics (NASDAQ:TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 after market close on Wednesday, February 15, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and ava

PLEASANTON, Calif., Nov. 2, 2022 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Revenue was $131.1 million for the third quarter, representing a 5% increase over the corresponding period of 2021 and a 14% increase over second quarter of 2022.Published a preprint highlighting the power of the company's combined technologies – Chromium, Visium and Xenium – to draw important and previously inaccessible insights from human breast cancer FFPE tissue.Released Xenium data and a preview

PLEASANTON, Calif., Oct. 12, 2022 /PRNewswire/ -- 10x Genomics (NASDAQ:TXG) today announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 2, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 d

PLEASANTON, Calif., Aug. 8, 2022 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG) today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Revenue was $114.6 million for the second quarter, representing a 1% decrease over the corresponding period of 2021.Announced the breakthrough capability of single-cell analysis on FFPE samples with its recently launched Fixed RNA Profiling Kit.Began shipping Visium CytAssist, the company's first spatial instrument.Announced the hiring of Jim Wilbur, Ph.D., as Chief Commercial Officer."Our results this quarter fell short of our expectations as we navigated some macro headwinds, particularly outside of the United States

PLEASANTON, Calif., July 14, 2022 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a life sciences leader focused on mastering biology to advance human health, today announced that its preliminary revenue is expected to be approximately $114.5 million for the second quarter ended June 30, 2022. This represents an approximate 1% decrease from $115.8 million for the prior year period, and flat revenue sequentially. Preliminary geographic revenue for the second quarter is expected to be as follows: Americas revenue of approximately $70.9 million, an 8% increase over the prior yea

Q1 2022 revenue growth of 8% over prior year PLEASANTON, Calif., May 4, 2022 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG) today reported financial results for the first quarter ended March 31, 2022. Recent Highlights Revenue was $114.5 million for the first quarter, representing an 8% increase over the corresponding period of 2021.Showcased robust product roadmap at Xperience 2022 for the Chromium and Visium platforms and provided a first look into Xenium, the company's forthcoming In Situ platform.Launched two new products for fixed RNA profiling and nuclei isolation, desi

PLEASANTON, Calif., April 7, 2022 /PRNewswire/ -- 10x Genomics (NASDAQ:TXG) today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 4, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days a

PLEASANTON, Calif., Feb. 16, 2022 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG) today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided outlook for 2022. Recent Highlights Revenue was $490.5 million for the full year and $143.5 million for the fourth quarter of 2021, representing 64% and 28% increases over the corresponding periods of 2020 Increased our cumulative Chromium instruments sold to more than 3,500 as of the end of 2021, fueled by an enthusiastic response to our Chromium X Series instruments and continued demand for our Chromium Controller Advanced our leadership in spatial discovery research surpassing 200 publications and pre-p

PLEASANTON, Calif., Jan. 26, 2022 /PRNewswire/ -- 10x Genomics (NASDAQ:TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 after market close on Wednesday, February 16, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at www.10xgenomics.com. The webcast will be archived and avai

PLEASANTON, Calif., Nov. 3, 2021 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG) today reported financial results for the third quarter ended September 30, 2021. Recent Highlights Revenue was $125.3 million for the third quarter, representing a 74% increase over the corresponding period of 2020 and an 8% increase compared to the second quarter of 2021.   Began shipping the Chromium X instrument, providing flexible analysis of up to one million cells per experiment, and high-throughput Gene Expression and Immune Profiling consumables, enabling affordable and routine large-scale gene expression and multiomic analyses.   Continued the strong momentum of customer publications by surpassing 3,000

PLEASANTON, Calif., Oct. 7, 2021 /PRNewswire/ -- 10x Genomics (NASDAQ:TXG) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event. About 10x Genomics10x Genomics is a life science technology company building products to interr

PLEASANTON, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ:TXG) today reported financial results for the second quarter ended June 30, 2021. Recent Highlights Revenue was $115.8 million for the second quarter, representing a 170% increase over the corresponding period of 2020 and a 9% increase compared to the first quarter of 2021Launched Chromium X, a next-generation instrument and platform for single cell analysis enabling million cell experiments and accelerating discoveries in areas including drug and CRISPR screens, large-scale translational studies, cell mapping, antibody discovery and biomarker identificationBegan shipping Visium Spatial Gene Expression for F